http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20010103577-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2fc2ed3380abdbfb4951506ca9cf89f5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b5b9f9cd8f41ddd9b8e5bc26a4d68518 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-208 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-79 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-5434 |
| filingDate | 2001-03-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9d7afb361e6caec78e2b56f92db7d712 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2e7e40e8dc85a10bf72f0f6fa6cdfb2d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4ae59c0bb192cc09065f799fb74b56b5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_83046854bb68bd496f6b18756cf72780 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3bbcfe08a0e0a922e492a89ebfe03841 |
| publicationDate | 2001-11-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-20010103577-A |
| titleOfInvention | Genes of IL-12p40 subunit mutated for improving the activity of IL-12 and use thereof for DNA vaccine adjuvant |
| abstract | The present invention is an IL-12p40 subunit mutant gene capable of producing highly active human and mouse Interleukin-12 (IL-12), an expression vector comprising the mutant gene, and use thereof as a DNA vaccine adjuvant. More specifically, the mutation of IL-12p40 by mutating the amino acid Asn-222 (human) or Asn-220 (mouse) of human or mouse IL-12p40, which acts as a competitive inhibitor of active IL-12 The IL-12p40 mutant gene allows IL-12p70, which has the immune activity of IL-12 to be secreted, to be secreted normally. The IL-12p40 subunit mutant gene of the present invention and IL-12p35 gene, another subunit of IL-12, can be used together for immunization with DNA vaccine against enveloped glycoprotein 2 (E2) of hepatitis C virus (HCV). In the case of HCV-E2 DNA alone or when IL-12p40 normal gene was used, it was found that it can induce and maintain an optimal cellular immune response for a longer time. Thus, these results confirm that IL-12p70, excluding IL-12p40 subunit, can elicit a long-term strong cellular immune response in vivo, and the IL-12p40 mutant gene of the present invention has a cellular immune response. It will be useful for gene therapy for the prevention and treatment of acquired immunodeficiency syndrome (AIDS), hepatitis C and B, cancer, flu, tuberculosis, malaria, etc., which are known to be indispensable. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-100788930-B1 |
| priorityDate | 2000-03-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 338.